Scope note. This paper provides measurement review and fitness and wellness education. It does not diagnose, treat, prescribe, manage medication, clinically interpret abnormal findings, or guarantee muscle preservation. Questions about symptoms, nutrition therapy, medications, or medical care belong with the appropriate licensed professional.

The scale is highly competent at one task. It records total body weight.

After a substantial change - twenty pounds, forty pounds, sometimes more - that number can feel conclusive. Clothing fits differently. Movement may feel easier. The effort or treatment appears to be working.

Then a body-composition report introduces another number: lean mass declined.

For many adults using GLP-1-based medication, this is where clarity gives way to alarm. A percentage is detached from the method that produced it and recast as "muscle loss." A population average is applied to one person. Two scans taken under different conditions are treated as though they were consecutive frames from the same film.

The evidence supports a more disciplined reading.

Intentional weight loss commonly changes more than one tissue compartment. Body-composition technologies estimate those compartments; they do not observe every tissue directly. Strength and physical capability can move differently from a lean-mass estimate. The quality of the comparison must be examined before the result is given meaning.

The useful question is larger than How much did I lose?
It is: What appears to have changed, how confidently can we say it changed, and what should the next phase protect or improve?

The scale records the outcome, not its composition

A scale cannot distinguish fat mass from lean soft tissue, body water, bone mineral, glycogen, or other contributors to total weight.

That limitation matters because substantial weight loss is rarely a pure reduction in fat. In the exploratory body-composition analysis from STEP 1, 140 participants underwent dual-energy X-ray absorptiometry, or DXA, during 68 weeks of semaglutide treatment or placebo. In the semaglutide group, body weight decreased by 15.0%, total fat mass by 19.3%, and total lean body mass by 9.7%. Because fat mass declined more, lean mass represented a larger share of the smaller final body weight.1,2

The SURMOUNT-1 DXA substudy followed 160 participants with baseline and week-72 scans. In the pooled tirzepatide groups, mean body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. Approximately 75% of the weight lost was categorized as fat mass and 25% as lean mass. A similar proportional partition appeared in the placebo group, although total loss was much smaller.3

These studies establish that measured lean mass can decline during meaningful weight loss. They do not provide a personal forecast.

STEP 1 and SURMOUNT-1 used different populations, durations, protocols, medications, and analytical approaches. Their body-composition samples were subsets of larger trials. The results should not be converted into a universal "acceptable ratio" or treated as a head-to-head ranking of medications.

"Lean mass" is a compartment, not a muscle biopsy

The language on a report can sound more anatomically specific than the measurement is.

DXA separates the body into estimated fat mass, lean soft tissue, and bone mineral content. Its lean category includes more than contractile skeletal muscle. It is influenced by body water and includes nonfat soft tissues throughout the body. The International Society for Clinical Densitometry treats total lean mass as a body-composition measure with defined acquisition, quality-control, and precision requirements - not as a direct assay of muscle fibers.4

A statement such as "25% of the weight lost was lean mass" describes the composition of total weight change under a particular measurement model. It does not mean that one quarter of a person's skeletal muscle disappeared. It also says nothing directly about force production, balance, endurance, or confidence.

Hydration and glycogen add another layer. Controlled research has shown that dehydration followed by rehydration and carbohydrate loading can shift DXA lean-tissue estimates over short periods - far too quickly to represent equivalent changes in contractile tissue.5

This does not make DXA unhelpful. It makes protocol discipline essential.

Quantity, quality, and function can diverge

Newer research is beginning to separate muscle size from muscle composition and performance.

A 2025 post-hoc analysis of SURPASS-3 MRI examined muscle volume and muscle fat infiltration in adults with type 2 diabetes. Tirzepatide was associated with lower muscle volume, broadly in line with the relationship between weight loss and muscle-volume change seen in comparison data. It was also associated with reduced muscle fat infiltration - a potentially favorable change in muscle composition. The exploratory analysis did not establish how every participant's strength or function changed.6

The SEMALEAN prospective cohort followed adults with obesity receiving semaglutide 2.4 mg. Among 106 participants who completed 12 months, mean weight declined 13% and fat mass declined 18%. Lean mass fell by approximately 3 kilograms by month seven and then stabilized, while average handgrip strength increased by 4.5 kilograms at month 12. The cohort had a high mean baseline body mass index and no randomized comparison group, limiting broader conclusions.7

It still demonstrates why lean-mass estimates and capability measures belong in the same review.

A body can become lighter, carry less fat, register less lean tissue, and perform better in selected tasks. Another person can show a similar composition pattern while capability declines. The scan alone cannot distinguish those stories.

Group averages cannot answer an individual question

Clinical trials estimate average effects across defined groups. Individual outcomes vary.

Age, starting body size, magnitude of weight loss, training history, nutrition, illness, injury, sleep, medication tolerance, and measurement conditions can all influence the observed pattern. A trial average cannot tell one client how much of a change reflects skeletal muscle, water, glycogen, other lean tissues, or technical variation.

A favorable fat-to-lean ratio does not guarantee that strength was maintained. A decline in lean mass does not, by itself, prove meaningful muscle impairment. The result is one signal inside a broader record.

For Opus Body, that record has four parts:

  • Composition: What did the measurement estimate?
  • Comparison quality: How defensible is the change between tests?
  • Capability: What can the person repeatedly do now?
  • Context: What occurred between measurements that could influence the result?

Comparison quality is part of the result

A precise number can come from an imprecise comparison.

For serial DXA body-composition measurements, the ISCD emphasizes consistent preparation and positioning, facility-specific precision assessment, quality control, and cross-calibration when systems change. It also states that an in-vivo cross-calibration study is necessary when comparing body-composition results across manufacturers.4

A strong comparison usually includes:

  • The same measurement method and, preferably, the same device.
  • Similar time of day, food and fluid status, clothing, and recent exercise.
  • Consistent positioning and analysis procedures.
  • Enough change to exceed the facility's expected measurement variability.
  • A record of intervening weight change, training, illness, travel, or other relevant conditions.

A weak comparison may involve different technologies or facilities, unrelated scanner manufacturers, markedly different hydration states, strenuous exercise before one test, or no preparation record. The earlier report may remain useful as history, while the language becomes more qualified: directionally consistent with change rather than confirmed muscle loss.

Confidence should follow the quality of the evidence, not the number of decimal places on the report.

Capability provides the second axis

Most adults in midlife are not trying to preserve lean mass as an abstract inventory. They want to rise from low seating, manage stairs and grades, carry luggage, move confidently on uneven ground, continue sports, and travel without quietly narrowing the itinerary.

A capability baseline gives those aims a repeatable form. Depending on the individual, it may include a controlled lower-body task, an upper-body strength measure, a carry, a walking or stair task, and an appropriately selected balance measure. These are fitness and wellness reference points, not diagnostic examinations.

Resistance exercise deserves a defined place in the record. In a randomized trial involving older adults with obesity undergoing intentional weight loss, the group combining weight loss with resistance training lost less lean mass than the group combining weight loss with aerobic training. Changes in knee-extensor strength were also associated with changes in lean mass.8 A separate randomized trial found that combined aerobic and resistance exercise produced broader improvements in physical function than either mode alone in dieting older adults with obesity.9

No exercise approach guarantees muscle preservation. Training has to fit current capacity, experience, orthopedic history, and healthcare guidance. The evidence supports a narrower conclusion: progressive resistance work and capability tracking are relevant during substantial weight change.

A defensible next 12 weeks

The next phase should be specific enough to guide action and restrained enough to execute.

1. Establish the baseline

Record the current body-composition method, testing conditions, relevant context, and a small set of capability measures. Review prior reports for comparability before placing their numbers on one trend line.

2. Create a repeatable strength exposure

Build a consistent, appropriately progressive pattern rather than an aggressive corrective campaign prompted by one scan. A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society places strength training and adequate nutrition among the priorities that may support adults receiving GLP-1-based therapy.10

Exercise selection and loading should remain within the client's abilities and any applicable guidance from licensed clinicians.

3. Review whether intake supports the phase

Appetite reduction can alter meal size, food variety, training support, and recovery. A measurement review can identify nutrition as a priority. Individualized nutrition therapy, gastrointestinal concerns, and medication questions belong with the prescribing clinician or a qualified registered dietitian.

4. Track capability without turning life into a laboratory

Use a limited set of repeatable measures to observe whether strength, control, carrying tolerance, or walking capacity is stable, improving, or declining.

The useful signal may be an easier set of stairs, a more controlled carry, greater confidence rising from the floor, additional repetitions at the same load, or better tolerance for a long day of walking. The point is not constant testing. It is a consistent record.

5. Preselect the retesting protocol

Define the follow-up protocol at baseline: method, facility, device where available, appointment timing, preparation, recent-exercise standard, and contextual notes. Reproduce those conditions as closely as practical.

Twelve weeks creates a useful horizon for reviewing execution and direction. It does not promise that every composition value will move beyond technical variability.

Reading the pattern at the retest

Lower fat mass with stable or improving capability presents a coherent direction, even when some decline in lean tissue is estimated.

A lower lean-mass estimate with stable strength calls for review of total weight change, hydration, testing preparation, device consistency, and training exposure before a firm conclusion is drawn.

Stable body weight with improved capability or a favorable composition estimate may also represent meaningful progress.

A material decline in function, persistent symptoms, medication concerns, or an abnormal finding requires referral to the appropriate licensed healthcare professional. Opus Body does not diagnose, treat, prescribe, manage medication, or clinically interpret abnormal findings.

Its role is focused: measurement review, comparison-quality assessment, capability baselining, fitness and wellness education, 12-week priority setting, and a repeatable retesting protocol.

After significant weight loss, the body deserves a more exact inquiry: what changed, what remains uncertain, whether capability is holding, and which few priorities deserve the next twelve weeks.

That approach creates a coherent record - one designed to support strength, capability, and confidence through the phase that follows the weight loss.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183.
  2. Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(suppl 1):A16-A17. doi:10.1210/jendso/bvab048.030.
  3. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275.
  4. International Society for Clinical Densitometry. 2023 ISCD Official Adult Positions: Body Composition and DXA Quality Standards. Accessed June 20, 2026. Official positions.
  5. Toomey CM, McCormack WG, Jakeman P. The effect of hydration status on the measurement of lean tissue mass by dual-energy X-ray absorptiometry. Eur J Appl Physiol. 2017;117(3):567-574. doi:10.1007/s00421-017-3552-x.
  6. Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(6):482-493. doi:10.1016/S2213-8587(25)00027-0.
  7. Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141.
  8. Beavers KM, Ambrosius WT, Rejeski WJ, et al. Effect of exercise type during intentional weight loss on body composition in older adults with obesity. Obesity (Silver Spring). 2017;25(11):1823-1829. doi:10.1002/oby.21977.
  9. Villareal DT, Aguirre L, Gurney AB, et al. Aerobic or resistance exercise, or both, in dieting older adults with obesity. N Engl J Med. 2017;376(20):1943-1955. doi:10.1056/NEJMoa1616338.
  10. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.